(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

What is cystic fibrosis liver disease? Liver disease associated with cystic fibrosis (CF) has been increasingly diagnosed during recent years, most likely due to the combined effect of systematic ...

Some airline passengers are gross. I pay my fare like everyone else and always wait for my turn to board. Does it matter if I get onto the flight five minutes after somebody else? Why do people ...

The Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center will collaborate with GSK to develop stem cell-based models to better understand pulmonary fibrosis and ...

The gross proceeds to the Company from the ... developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need.

Happy Tuesday! Here’s your Tuesday Tech Drop, the week’s top stories from the intersection of politics and the all-inclusive world of technology. U.S. intelligence officials say a Russian ...

The primary goal of the research will be to understand how dysfunctional lung epithelial cells contribute to causing and perpetuating pulmonary fibrosis, according to the release. These cells ...